HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

Journal of Hepatology

Volumn 46, Issue 4, 2007, Pages 635-644

  Rosenau, Jens ^a   Kreutz, Therese ^a   Kujawa, Matthias ^a   Bahr, Matthias J ^a   Rifai, Kinan ^a   Hooman, Nazanin ^a   Finger, Andrea ^a   Michel, Gerd ^c   Nashan, Björn ^a   Kuse, Ernst R ^b   Klempnauer, Jürgen ^b   Tillmann, Hans L ^d   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Kinetic; Prophylaxis; Reinfection; Surface antigen

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KINETICS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME;

ADULT; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; KINETICS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RECURRENCE;

EID: 33947190561     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.11.022     Document Type: Article

References (48)

1. Todo S., Demetris A.J., Van Thiel D., Teperman L., Fung J.J., and Starzl T.E. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13 (1991) 619-626
2. Eason J.D., Freeman Jr. R.B., Rohrer R.J., Lewis W.D., Jenkins R., Dienstag J., et al. Should liver transplantation be performed for patients with hepatitis B?. Transplantation 57 (1994) 1588-1593
3. Angus P.W. Review: hepatitis B and liver transplantation. J Gastroenterol Hepatol 12 (1997) 217-223
4. Devlin J., Smith H.M., O'Grady J.G., Portmann B., Tan K.C., and Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 21 (1994) 204-210
5. Grazi G.L., Mazziotti A., Sama C., Jovine E., Stefanini F., Paladini R., et al. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transpl Surg 2 (1996) 418-425
6. Grellier L., and Dusheiko G.M. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 4 (1997) 111-116
7. Gugenheim J., Baldini E., Ouzan D., and Mouiel J. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc 29 (1997) 517-518
8. Konig V., Hopf U., Neuhaus P., Bauditz J., Schmidt C.A., Blumhardt G., et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 58 (1994) 553-559
9. Langrehr J.M., Lemmens H.P., Keck H., Lohmann R., Knoop M., Neumann U., et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. Transplant Proc 27 (1995) 1215-1216
10. Lee W.C., Jeng L.B., Wang C.C., Chen M.F., Chien R.N., Chiu C.T., et al. Long-term immunoprophylaxis for hepatitis B virus reinfection after liver transplantation. Transplant Proc 28 (1996) 1699-1700
11. Lemmens H.P., Langrehr J.M., Blumhardt G., Lohmann R., Knoop M., Verschl J., et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. Transplant Proc 26 (1994) 3622-3623
12. Lerut J.P., Donataccio M., Ciccarelli O., Roggen F., Jamart J., Laterre P.F., et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 30 (1999) 706-714
13. Nymann T., Shokouh-Amiri M.H., Vera S.R., Riely C.A., Alloway R.R., and Gaber A.O. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 10 (1996) 663-667
14. Terrault N.A., and Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 7 (2003) 537-550
15. Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol 34 (2001) 943-945
16. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
17. Lok A.S. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 8 (2002) S67-S73
18. al-Hemsi B., McGory R.W., Shepard B., Ishitani M.B., Stevenson W.C., McCullough C., and Pruett T.L. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 10 (1996) 668-675
19. Sawyer R.G., McGory R.W., Gaffey M.J., McCullough C.C., Shephard B.L., Houlgrave C.W., et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 227 (1998) 841-850
20. Lucey M.R., Graham D.M., Martin P., Di Bisceglie A., Rosenthal S., Waggoner J.G., et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 33 (1992) 1390-1396
21. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
22. Lauchart W., Muller R., and Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 19 (1987) 4051-4053
23. McGory R.W., Ishitani M.B., Oliveira W.M., Stevenson W.C., McCullough C.S., Dickson R.C., et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 61 (1996) 1358-1364
24. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A.K., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
25. Lo C.M., Cheung S.T., Lai C.L., Liu C.L., Ng I.O., Yuen M.F., et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 233 (2001) 276-281
26. Mutimer D., Dusheiko G., Barrett C., Grellier L., Ahmed M., Anschuetz G., et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 70 (2000) 809-815
27. Mutimer D., Pillay D., Dragon E., Tang H., Ahmed M., O'Donnell K., et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30 (1999) 715-721
28. Mutimer D., Pillay D., Shields P., Cane P., Ratcliffe D., Martin B., et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 46 (2000) 107-113
29. Neff G.W., O'Brien C.B., Nery J., Shire N., Montalbano M., Ruiz P., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 10 (2004) 1372-1378
30. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
31. Zheng S., Chen Y., Liang T., Lu A., Wang W., Shen Y., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 12 (2006) 253-258
32. Lo C.M., Liu C.L., Lau G.K., Chan S.C., Ng I.O., and Fan S.T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 11 (2005) 807-813
33. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yersiz H., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
34. Rosenau J., Bahr M.J., Tillmann H.L., Trautwein C., Klempnauer J., Manns M.P., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
35. Yoshida E.M., Erb S.R., Partovi N., Scudamore C.H., Chung S.W., Frighetto L., et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 5 (1999) 520-525
36. Yao F.Y., Osorio R.W., Roberts J.P., Poordad F.F., Briceno M.N., Garcia-Kennedy R., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 5 (1999) 491-496
37. Naoumov N.V., Lopes A.R., Burra P., Caccamo L., Iemmolo R.M., de Man R.A., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 34 (2001) 888-894
38. Marzan A., Salizzoni M., Debernardi-Venon W., Smedile A., Franchello A., Ciancio A., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34 (2001) 903-910
39. Dumortier J., Chevallier P., Scoazec J.Y., Berger F., and Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 3 (2003) 999-1002
40. Angus P.W., McCaughan G.W., Gane E.J., Crawford D.H., and Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 6 (2000) 429-433
41. Seehofer D., Rayes N., Steinmuller T., Neuhaus R., Berg T., Muller A.R., et al. Liver transplantation in hepatitis B patients with preoperative resistance formation during lamivudine treatment. Transplant Proc 34 (2002) 2274-2275
42. Ferretti G., Merli M., Ginanni Corradini S., Callejon V., Tanzilli P., Masini A., et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36 (2004) 535-538
43. Buti M., Mas A., Prieto M., Casafont F., Gonzalez A., Miras M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811-817
44. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 38 (2003) 86-95
45. Dickson R.C., Terrault N.A., Ishitani M., Reddy K.R., Sheiner P., Luketic V., et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 12 (2006) 124-133
46. Marzano A., Lampertico P., Mazzaferro V., Carenzi S., Vigano M., Romito R., et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 11 (2005) 532-538
47. Thurmann P.A., Sonnenburg C., Valentova K., Gregora E., Freischlager F., and Lissner R. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. Eur J Clin Pharmacol 57 (2001) 235-241
48. Marzano A., Gaia S., Ghisetti V., Carenzi S., Premoli A., Debernardi-Venon W., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11 (2005) 402-409